CRVO - NASDAQ
CervoMed Inc.
$5.50
-0.36%CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
At a Glance
Live SnapshotCervoMed Inc. Management Team
Mr. William Robert Elder J.D.
Chief Financial Officer, General Counsel & Corporate Secretary
Compensation
$548,741
Dr. Robert J. Cobuzzi Jr., Ph.D.
Chief Operating Officer & Director
Compensation
$710,225
Dr. Sylvie L. Gregoire Pharm.D.
Co-Founder & Director
Compensation
$42,537
Dr. John J. Alam M.D.
Co-Founder, Chief Executive Officer, President & Director
Compensation
$807,803
Ms. Kelly Blackburn M.H.A.
Executive Vice President of Clinical Development
Compensation
$404,940
Dr. Mark A. De Rosch Ph.D.
Executive Vice President of Regulatory, Government Affairs & Program Management
Dr. Claudia Ordonez M.D.
Senior Vice President of Medical Science
CervoMed Inc. Insider Positioning
During the last 12 months, insiders have purchased $610K worth of CRVO shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
30.4K
240.41K
0
0.00
+240K
+$240K
9-12 Months
56.7K
369.68K
0
0.00
+370K
+$370K
Top Buyers
Gregoire Sylvie
Director, 10 Percent Owner:
$185K
Alam John J
Director, 10 Percent Owner, Officer: Ceo & President
$94K
Sabbagh Marwan
Director
$53K
Poulton Jeffrey V.
Director
$53K
Hollingsworth Jane H
Director
$53K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $610K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
CRVO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 23, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 14, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | March 28, 2022 | April 14, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | February 28, 2022 | April 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 25, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 17, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 13, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 14, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 18, 2017 | November 01, 2017 | 2017 | |
DEF 14A DEF 14A 2017 N/A | May 12, 2017 | June 15, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.